Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.02 USD | +5.21% | +1.00% | +57.81% |
Business Summary
Number of employees: 30
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 16-01-03 |
Preston Klassen
PSD | President | 55 | 23-06-21 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 19-08-29 |
Rekha Garg
CTO | Chief Tech/Sci/R&D Officer | - | 22-11-28 |
Chief Tech/Sci/R&D Officer | - | 22-11-28 | |
Amin Kamel
PRN | Corporate Officer/Principal | - | 22-06-01 |
Daniel Penksa
AUD | Comptroller/Controller/Auditor | 39 | 15-05-31 |
Christopher Aker
LAW | General Counsel | 63 | 11-05-18 |
Brian K. Campion
PRN | Corporate Officer/Principal | - | 20-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 17-05-31 |
David Baltimore
BRD | Director/Board Member | 86 | 08-12-31 |
Director/Board Member | 75 | 13-03-31 | |
Chairman | 75 | 07-12-31 | |
Jake Nunn
BRD | Director/Board Member | 53 | 19-06-10 |
Alice Huang
BRD | Director/Board Member | 85 | 21-01-25 |
Hugh Rosen
BRD | Director/Board Member | 65 | 16-06-01 |
Joseph Hagan
CEO | Chief Executive Officer | 55 | 16-01-03 |
Preston Klassen
PSD | President | 55 | 23-06-21 |
Kathryn Collier
BRD | Director/Board Member | 56 | 18-04-16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 3,725,720 | 0 | 0 | 95.99 % |
Stock B | 0 | 258,707 | 0 | 0 | |
Stock C | 0 | 1,330,832 | 0 | 0 | |
Stock D | 1 | 65,465,876 | 64,363,679 ( 98.32 %) | 0 | |
Stock E | 0 | 256,700 | 0 | 0 |
Company contact information
Regulus Therapeutics, Inc.
4224 Campus Point Court Suite 210
92121, San Diego
+858 202 6300
http://www.regulusrx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.81% | 132M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.34% | 21.78B | |
-9.23% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- RGLS Stock
- Company Regulus Therapeutics Inc.